Melinda Magyari

Assisted reproductive technology treatment and the risk of MS 1:38
Assisted reproductive technology treatment and the risk of MS
Melinda Magyari • 28 Oct 2022
Post-authorization safety study of teriflunomide in MS 1:08
Post-authorization safety study of teriflunomide in MS
Melinda Magyari • 28 Oct 2022
Pregnancy planning: differences between counselling NMOSD and MS patients 2:26
Pregnancy planning: differences between counselling NMOSD and MS patients
Melinda Magyari • 28 Oct 2022
Challenging clinical decisions in pregnancy planning with MS and NMOSD patients 1:56
Challenging clinical decisions in pregnancy planning with MS and NMOSD patients
Melinda Magyari • 28 Oct 2022
Current treatment guidelines: pregnancy in MS and NMOSD 1:26
Current treatment guidelines: pregnancy in MS and NMOSD
Melinda Magyari • 28 Oct 2022
Sex differences in multiple sclerosis disease course over 25 years of follow up 4:53
Sex differences in multiple sclerosis disease course over 25 years of follow up
Melinda Magyari • 8 Apr 2022
Epidemiology and disease characteristics of late-onset MS 3:33
Epidemiology and disease characteristics of late-onset MS
Melinda Magyari • 29 Jun 2021
Comorbidities in multiple sclerosis patients 3:33
Comorbidities in multiple sclerosis patients
Melinda Magyari • 2 Nov 2020
Initial high-efficacy disease-modifying therapy in multiple sclerosis 2:57
Initial high-efficacy disease-modifying therapy in multiple sclerosis
Melinda Magyari • 2 Nov 2020
Are MS patients at increased risk for developing cancer? 1:17
Are MS patients at increased risk for developing cancer?
Melinda Magyari • 2 Nov 2020
The content of VJNeurology is intended for healthcare professionals